BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The firm has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,221
Employees3,221
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,221
Employees3,221

BMRN Key Statistics

Market cap
11.41B
Market cap11.41B
Price-Earnings ratio
43.05
Price-Earnings ratio43.05
Dividend yield
Dividend yield
Average volume
2.23M
Average volume2.23M
High today
$59.77
High today$59.77
Low today
$57.07
Low today$57.07
Open price
$57.31
Open price$57.31
Volume
3.71M
Volume3.71M
52 Week high
$66.28
52 Week high$66.28
52 Week low
$49.26
52 Week low$49.26

Stock Snapshot

The current BioMarin(BMRN) stock price is $58.60, with a market capitalization of 11.41B. The stock trades at a price-to-earnings (P/E) ratio of 43.05.

As of 2026-06-27, BioMarin(BMRN) stock has fluctuated between $57.07 and $59.77. The current price stands at $58.60, placing the stock +2.7% above today's low and -2.0% off the high.

The BioMarin(BMRN)'s current trading volume is 3.71M, compared to an average daily volume of 2.23M.

During the past year, BioMarin(BMRN) stock moved between $49.26 at its lowest and $66.28 at its peak.

During the past year, BioMarin(BMRN) stock moved between $49.26 at its lowest and $66.28 at its peak.

BMRN News

24/7 Wall St. 2d
BioMarin Earnings Report Q2 2025 | Beat, EPS & Revenue - 24/7 Wall St.

...

BioMarin Earnings Report Q2 2025 | Beat, EPS & Revenue - 24/7 Wall St.
Simply Wall St 5d
Did New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's Investment Narrative?

Earlier in June 2026, BioMarin Pharmaceutical reported new data at ENDO 2026 showing sustained growth benefits and a favorable safety profile for VOXZOGO in hyp...

Did New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's Investment Narrative?

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
20.7%
Sell
0%

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.